Infection Prevention and Management in Patients Receiving BMCA-Directed Bispecific
Hana Safah, MD, details the prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.
EP: 1.Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma (R/R MM)
EP: 2.Case 1: Treatment of R/R MM with a BCMA-Directed Bispecific Antibody
EP: 3.MajesTEC-1: Teclistamab in R/R MM Treatment
EP: 4.Selecting Patients with R/R MM for Treatment With Bispecifics
EP: 5.Infection Prevention and Management in Patients Receiving BMCA-Directed Bispecific
EP: 6.Selecting an Appropriate BCMA-Directed Bispecific for Patients with R/R MM
EP: 7.DREAMM-2: Belantamab Mafodotin for the Treatment of R/R MM
EP: 8.Case 2: Treatment of R/R MM with BCMA-Directed CAR T-Cell Therapy
EP: 9.CAR-T in R/R MM: Key Safety and Efficacy Data from the KarMMA and CARTITUDE-1 Trials
EP: 10.Selecting the Appropriate CAR T-Cell Therapy in R/R MM
EP: 11.Case 3: Sequencing BCMA-Directed Therapies for R/R MM
EP: 12.Unmet Needs in R/R MM and Clinical Practice Pearls
Khouri Discusses Selinexor Dosing and Management Approaches for R/R MM
July 22nd 2024During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.
Read More
New Hope for Multiple Myeloma: Cilta-Cel Improves Overall Survival
July 2nd 2024The CARTITUDE-4 study that found that treatment with cilta-cel led to a statistically significant and clinically meaningful improvement in overall survival among patients with relapsed and lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.
Read More
